Modularit offers an AI‑driven platform that designs interchangeable, modular receptor components for in vivo cell therapies, enabling rapid reconfiguration of ligand‑binding, signaling, and safety domains. The system generates high‑affinity, manufacturable receptors that integrate with viral or non‑viral delivery methods, reducing development time, manufacturing complexity, and cost for biotech and pharma programs targeting cancer, autoimmunity, and fibrosis.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
- Startup funding source · Source unavailable
Founders
Product
Problem
Cell therapies often rely on engineered receptors that are difficult to design, costly to produce, and can exhibit safety or efficacy limitations, restricting their use across oncology, autoimmunity, and fibrotic diseases.
Solution
Modularit provides a platform that creates interchangeable, modular receptor components for in vivo cell therapies. An AI‑driven protein design engine generates receptor variants optimized for binding specificity, signaling strength, and manufacturability. The modular architecture allows rapid swapping of ligand‑binding domains, signaling modules, and safety switches to tailor therapies for different disease targets. Produced receptors are engineered for stable expression in patient‑derived cells, reducing manufacturing complexity and enabling scalable, cost‑effective treatment pipelines. The platform integrates with existing cell‑therapy workflows, delivering validated receptor libraries that accelerate preclinical development and de‑risk clinical translation.
Target Audience
Primary customers are biotech firms and pharmaceutical R&D groups developing engineered cell therapies for cancer, autoimmune disorders, and fibrotic conditions.
Features
- AI‑based protein design pipeline that predicts high‑affinity binding and optimal signaling profiles
- Fully modular receptor architecture separating targeting, signaling, and safety domains for rapid reconfiguration
- Built‑in safety switches (e.g., inducible apoptosis, cytokine release control) to mitigate adverse events
- Compatibility with viral and non‑viral delivery methods for in vivo cell engineering
- Scalable production workflow that reduces reagent costs and accelerates GMP manufacturing
- Comprehensive validation suite including in vitro potency assays and in vivo efficacy models